Medical device maker Danaher Corp.’s COVID-19 blood test for detecting if a person had ever been infected with the new coronavirus received emergency use clearance from the U.S. Food and Drug Administration.
The governor of Texas temporarily halted the state’s reopening as COVID-19 infections and hospitalizations surged and the country set a new record for a one-day increase in cases.
Many studies assessing the accuracy of COVID-19 antibody tests had major shortcomings, a review concluded, offering further evidence the blood tests are of little use for people seeking to know with certainty if they have been infected.
Finch Therapeutics reported positive topline results from PRISM3, a Phase II trial of CP101, an oral microbiome drug for the prevention of recurrent C. difficile infection.
A specific mutation in the new coronavirus can significantly increase its ability to infect cells, according to a study by U.S. researchers.
A look at upcoming PDUFA dates for the U.S. Food and Drug Administration, including Viela Bio’s inebilizumab for NMOSD.
AstraZeneca’s cancer drug Calquence has shown initial signs of helping hospitalized COVID-19 patients get through the worst of the disease, as researchers scramble to repurpose existing treatments to help fight the deadly infection.
Children have milder COVID-19 symptoms than adults and the balance of evidence suggests they may also have lower susceptibility and infectivity than adults, scientists advising the British government said.
Weeks after Mammoth Biosciences announced the company’s CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the Bay Area-based firm struck a deal with GlaxoSmithKline to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
Prellis Biologics Inc. generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.
